Spotify's acquisition last week of the music licensing start-up Loudr helps the streaming service to better manage its costs so that it can focus on attracting new subscribers for its premium service, said a digital media investment banker who helped Loudr close the deal.
Loudr's services are intended to make it easier for content creators and digital music services to identify, track, and pay royalties to music publishers more efficiently. Royalties are, of course, part of Spotify's recurring costs.
"It makes sense for Spotify, which is the largest music streaming service in terms of paid users, to take control of this important piece," said Sun Jen Yung, a partner and the head of digital media at Nfluence Partners.
Loudr makes the complex process of paying royalties easier through automation, she said Wednesday in an interview on Cheddar.
This week, Spotify announced it will update its mobile app soon in an effort to make it easier to use.
"To the extent that they can attract more users, that can hopefully help them upgrade to a premium service," said Yung.
For full interview, [click here](https://cheddar.com/videos/inside-spotifys-acquisition-of-loudr).
Seth Schachner, Managing Director at Strat Americas, on Hollywood's latest blockbusters utilizing content creation. Plus, the future of YouTube and TikTok.
Ashley Gold, Axios' Tech/Policy reporter, discusses what the future of Google and search engines will look like after the tech giant faces an antitrust trial.
A labor rights group has alleged that Starbucks sourced coffee from a major Brazilian cooperative whose member farms were cited for keeping workers in slave-like conditions.
X, the social media platform owned by Trump adviser Elon Musk, is challenging the constitutionality of a Minnesota ban on using deepfakes to influence elections and harm candidates.
Seth Goldstein, Equity Strategist at Morningstar, breaks down Tesla's earnings report, talks Musk's future with the company and how stocks have responded.
Senior Health Correspondent for TIME, Alice Park, gives us a deeper look into how Eli Lilly's new pill orforglipron may change the healthcare industry.
